Edition:
United Kingdom

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,061
52-wk High
$3.69
52-wk Low
$1.66

Select another date:

Wed, Nov 15 2017

BRIEF-‍Stonepine Capital Management reports 6.6 pct passive stake in Vical

* ‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​ Source text: (http://bit.ly/2z2Y7Nh) Further company coverage:

BRIEF-Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock

* Vical Incorporated announces pricing of $25 million underwritten public offering of common stock

BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION

* VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION

BRIEF-Vical reports Q3 loss per share $0.27

* Vical reports third quarter 2017 financial and operational results

BRIEF-Vical Inc files for common stock offering of up to $23.0 mln

* Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​ Source: (http://bit.ly/2gnoSUA) Further company coverage:

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA

* Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial

BRIEF-Vical Inc Q2 loss per share $0.30

* Vical reports second quarter 2017 financial and operational results

Select another date: